BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19102383)

  • 1. Prophylaxis against recurrence of HBV hepatitis after living-donor liver transplantation.
    Tashiro H; Itamoto T; Fudaba Y; Ohdan H; Fukuda S; Kohashi T; Amano H; Ishiyama K; Ide K; Ogawa T; Shishida M; Irei T; Ushitora Y; Ohira M; Takahashi S; Chayama K; Asahara T
    Hepatogastroenterology; 2008; 55(86-87):1746-9. PubMed ID: 19102383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B prophylaxis in living donor liver transplantation: single center experience.
    Yaprak O; Dayangac M; Balci D; Bas K; Yuzer Y; Tokat Y
    Hepatogastroenterology; 2010; 57(102-103):1178-82. PubMed ID: 21410054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.
    Angus PW; McCaughan GW; Gane EJ; Crawford DH; Harley H
    Liver Transpl; 2000 Jul; 6(4):429-33. PubMed ID: 10915163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
    Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
    Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
    Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
    Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
    Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
    Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.
    Na GH; Kim DG; Han JH; Kim EY; Lee SH; Hong TH; You YK; Choi JY
    J Gastroenterol Hepatol; 2014 Jan; 29(1):151-6. PubMed ID: 24117684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
    Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
    Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
    Dodson SF; de Vera ME; Bonham CA; Geller DA; Rakela J; Fung JJ
    Liver Transpl; 2000 Jul; 6(4):434-9. PubMed ID: 10915164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
    Liu J; Wu GC; Zhang ZT; Wu P; Zhang D; Sun MC; Gao DC; Wang Y; Jia JD; Wang BE
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):976-9. PubMed ID: 16194352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of hepatitis B recurrence after liver transplantation using lamivudine and hepatitis B immune globulin.
    Ołdakowska-Jedynak U; Paczek L; Foroncewicz B; Mucha K; Nyckowski P; Zieniewicz K; Ziarkiewicz-Wróblewska B; Ziółkowski J; Pilecki T; Patkowski W; Górnicka B; Paczkowska A; Krawczyk M
    Ann Transplant; 2007; 12(3):28-32. PubMed ID: 18290567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy.
    Hwang S; Lee SG; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Park JI; Ryu JH; Lee HJ; Suh DJ; Lim YS
    Liver Transpl; 2008 Jun; 14(6):770-8. PubMed ID: 18508369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
    Stärkel P; Stoffel M; Lerut J; Horsmans Y
    Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens.
    Anderson RD; Chinnakotla S; Guo L; Perrillo RP; Klintmalm GB; Davis GL
    Clin Transplant; 2007; 21(4):510-7. PubMed ID: 17645711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database.
    Park GC; Hwang S; Kim MS; Jung DH; Song GW; Lee KW; Kim JM; Lee JG; Ryu JH; Choi DL; Wang HJ; Kim BW; Kim DS; Nah YW; You YK; Kang KJ; Yu HC; Park YH; Lee KJ; Kim YK
    J Korean Med Sci; 2020 Feb; 35(6):e36. PubMed ID: 32056398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.